The efficacy of GLOPERBA® is well established1,7

Allopurinol alone is not enough7

An 82% reduction in gout flares after 6 months of colchicine prophylaxis:
Colchicine prophylaxis* + ULT significantly reduced the frequency of gout flares vs ULT alone

*GLOPERBA® is an approved NDA based on the demonstrated bioequivalence of a 0.6 mg colchicine tablet with 5 mL (0.6 mg) of GLOPERBA solution. The efficacy data presented here are from the study of 0.6 mg of colchicine for the prophylaxis of gout flares.
ULT = urate lowering therapy.

The safety profile of GLOPERBA is well characterized7

A lack of precision dosing has the potential to lead to colchicine toxicity2,3


The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain1

The use of colchicine in the management of chronic gout has been studied for decades.1,17,18

  • The safety of colchicine as a part of gout-flare prophylaxis has been well established
  • The safety of colchicine is backed by over 60 years of real-world experience

Patients with renal or hepatic impairment should not be given GLOPERBA in conjunction with both CYP3A4 and P-gp inhibitors. In these patients, life threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.